How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Yahoo! Finance
with acquired hypothalamic obesity, supported by positive Phase 3 TRANSCEND data in this rare, brain-injury–related form of obesity. At the same time, Rhythm named PANTHERx Rare Pharmacy as exclusive U.S. distributor for the new indication, highlighting a tightly focused access and support model for this underserved patient group. We'll now examine how IMCIVREE's first-in-class approval in acquired hypothalamic obesity interacts with Rhythm's existing investment narrative and expectations. Uncover the next big thing with 33 elite penny stocks that balance risk and reward. Rhythm Pharmaceuticals Investment Narrative Recap To own Rhythm, you need to believe IMCIVREE can scale across tightly defined rare obesity segments while the company manages sizable losses and heavy reliance on a single drug. The newly approved acquired hypothalamic obesity indication is a meaningful near term catalyst, but it does not remove the key risk around ongoing operating losses and potential dilut
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide [Yahoo! Finance]Yahoo! Finance
- Rhythm obesity drug wins broader use from FDA [Yahoo! Finance]Yahoo! Finance
- PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)PR Newswire
- Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide [Yahoo! Finance]Yahoo! Finance
RYTM
Earnings
- 2/26/26 - Beat
RYTM
Sec Filings
- 3/20/26 - Form 8-K
- 3/16/26 - Form 8-K
- 3/16/26 - Form 4
- RYTM's page on the SEC website